Expert Insights and Strategies to Improve Multiple Myeloma Care in an Environment of Continually Expanding Treatment Options and Clinical Complexity

Gain expert insight on myeloma treatment in this comprehensive educational program. Compare your choice of therapy against a panel of experts in the Interactive Decision Support Tool, read through the CME-certified module and ClinicalThought commentaries, and watch the video modules to review strategies for diagnosis, treatment, safety considerations, and investigational agents in myeloma care.
Sagar Lonial, MD
Program Director
Irene M. Ghobrial, MD
Carol Ann Huff, MD
Shaji Kumar, MD
Sagar Lonial, MD
Noopur Raje, MD

ClinicalThought

New data from ASH 2017 raise many questions regarding how these new approaches will fit into the current treatment paradigm for patients with myeloma.

Shaji Kumar, MD Released: January 29, 2018

Carol Ann Huff, MD, discusses the clinical impact of the monoclonal antibody daratumumab for the treatment of patients with multiple myeloma, with practical insights for using this agent in your practice.

Carol Ann Huff, MD Released: March 2, 2018

Shaji Kumar, MD, provides an overview of the latest research on smoldering multiple myeloma, with treatment strategies to consider for your patients.

Shaji Kumar, MD Released: April 18, 2018

Expert commentary on the clinical implications of the OPTIMISMM trial of pomalidomide combinations in early-relapse multiple myeloma.

Sagar Lonial, MD Released: July 25, 2018

Now that 3 effective proteasome inhibitors are approved by the FDA for multiple myeloma, read how to select the optimal agent for your patients considering dosing, safety profiles, and efficacy in risk-defined subgroups.

Noopur Raje, MD Released: August 24, 2018

New data for managing lenalidomide-refractory patients, evolving carfilzomib dosing, and CAR T-cell therapy hold significant potential to improve outcomes in relapsed/refractory multiple myeloma.

Shaji Kumar, MD Released: October 29, 2018

Module

Examine best practice treatment options for patients with transplantation-eligible and transplantation-ineligible multiple myeloma, with expert commentary and interactive cases.

Shaji Kumar, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 3, 2018 Expiration: October 2, 2019

In this downloadable slideset from the multiple myeloma online program, Shaji Kumar, MD, provides expert perspective for the optimal management of patients with multiple myeloma.

Shaji Kumar, MD Released: October 3, 2018

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with myeloma with those of experts Irene M. Ghobrial, MD; Carol Ann Huff, MD; Shaji Kumar, MD; Sagar Lonial, MD; and Noopur Raje, MD.

Irene M. Ghobrial, MD Carol Ann Huff, MD Shaji Kumar, MD Sagar Lonial, MD Noopur Raje, MD Released: July 20, 2018

Video Modules

In this video, Sagar Lonial, MD, provides insight on diagnosis and optimal management of patients with smoldering myeloma, based on current clinical evidence.

Sagar Lonial, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: May 31, 2018 Expiration: May 30, 2019

Watch this video to hear when Sagar Lonial, MD, recommends transplantation for his patients with newly diagnosed myeloma.

Sagar Lonial, MD
Program Director
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: July 24, 2018 Expiration: July 23, 2019

Watch this video to see how Sagar Lonial, MD, uses genetic and disease risk factors to personalize maintenance strategies after autologous SCT for his patients with multiple myeloma.

Sagar Lonial, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 16, 2018 Expiration: August 15, 2019
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Celgene Corporation
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?